Neuro-Care Sp. z o.o. sp.k.
- Address
- Ul. Pawla Kolodzieja 8, 40-749 Katowice, Poland
Musculoskeletal Diseases
The site focuses on improving treatment options for conditions that affect the musculoskeletal system, with particular attention to neuropathic pain and related sensory disorders. Researchers are evaluating new therapies aimed at reducing pain intensity and enhancing quality of life for patients suffering from peripheral nerve complications.
- Diabetic peripheral neuropathic pain
- Distal sensory polyneuropathy
- Post‑herpetic neuralgia
- Chronic musculoskeletal pain syndromes
Neuro‑Care Sp. z o.o. sp.k. leverages its multidisciplinary team to advance pain management strategies, seeking safer and more effective alternatives to current standards.
Nervous System Diseases
Clinical research at the Katowice centre targets a broad range of neurodegenerative and neuroinflammatory disorders. Ongoing studies aim to slow disease progression, improve motor function, and preserve cognitive abilities in patients with early and advanced stages of these illnesses.
- Alzheimer disease and early symptomatic stages
- Parkinson disease, including motor fluctuations
- Multiple sclerosis, relapsing‑remitting and progressive forms
- Multiple system atrophy and other tauopathies
The investigators at Neuro‑Care are testing innovative agents and delivery methods to enhance neurological outcomes and support long‑term safety.
Mental Disorders
Research in the mental health arena concentrates on psychiatric symptoms associated with neurodegenerative conditions and primary mood disorders. Trials are designed to assess the efficacy of novel compounds in reducing psychosis, apathy, and other behavioral disturbances, thereby improving daily functioning.
- Psychosis linked to Alzheimer disease
- Apathy in Parkinson disease
- Mental health aspects of chronic neurological illness
- Preventive strategies for migraine and menstrual migraine
Through collaborative efforts, Neuro‑Care aims to deliver safer, targeted therapies that address both cognitive and emotional challenges faced by patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1F. Hoffmann-La Roche AG2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG7trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Neuro-Care Sp. z o.o. sp.k.
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis | F. Hoffmann-La Roche AG | Phase II | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Florbetaben (18F) | 3 | Unknown | 2024-03-29 | 2025-11-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.